SCHEMBL4975964

SCHEMBL4975964

CCc1cccc2ncn(CC(=O)Nc3cc(OC)cc(C(F)(F)F)c3)c12

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.48
LMNA P02545 4/20 0.44
POLB P06746 3/20 0.44
RAF1 P04049 2/20 0.43
BRAF P15056 2/20 0.43
MAPT P10636 4/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
KDR P35968 1/20 0.41
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.41
NTRK1 P04629 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TMPRSS4 Q9NRS4 1/20 0.41
FPR1 P21462 1/20 0.41
FPR2 P25090 1/20 0.41
NR2E1 Q9Y466 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4975749 0.92 RXFP1 (0.46) RXFP1LMNAPOLBRAF1BRAF
SCHEMBL4974004 0.88 RXFP1 (0.47) RXFP1POLBRAF1BRAFMAPT
SCHEMBL4465214 0.88 RXFP1 (0.47) RXFP1LMNAPOLBRAF1BRAF
SCHEMBL3042696 0.88 RXFP1 (0.47) RXFP1LMNAPOLBRAF1BRAF
SCHEMBL3034826 0.87 RXFP1 (0.47) RXFP1LMNAPOLBRAF1BRAF
SCHEMBL4977861 0.87 RXFP1 (0.47) RXFP1LMNAPOLBRAF1BRAF
SCHEMBL4462916 0.87 RXFP1 (0.47) RXFP1LMNAPOLBRAF1BRAF
SCHEMBL4974192 0.87 RXFP1 (0.47) RXFP1LMNAPOLBRAF1BRAF
SCHEMBL4976395 0.86 RXFP1 (0.46) RXFP1LMNAPOLBRAF1BRAF
SCHEMBL4972985 0.86 RXFP1 (0.46) RXFP1LMNAPOLBRAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP claimed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO claimed
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US disclosed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP disclosed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015222-A1 New Heterocyclic Amides AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 RXFP1 1473/4885LMNA 2368/4885POLB 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.